Literature DB >> 2058609

A survey of antiemetic use in children with cancer.

J van Hoff1, M J Hockenberry-Eaton, K Patterson, J J Hutter.   

Abstract

Pediatric oncologists within Pediatric Oncology Group institutions were surveyed to determine current antiemetic practices for children receiving chemotherapy and the basis for those practices. A mean severity rating for associated nausea and vomiting was calculated and used to rank 31 chemotherapeutic agents commonly used in the treatment of childhood cancer. Antiemetics were used 17%, 79%, and 98% of the time for chemotherapeutic agents with mild, moderate, or severe associated nausea and vomiting, respectively. A median of one, two, and three antiemetics were used for mild, moderate, and severe agents, respectively. Antihistamines and phenothiazines were the drugs most commonly used for agents causing mild or moderate nausea and vomiting, and metoclopramide hydrochloride/antihistamines with lorazepam and/or corticosteroids were used most often for chemotherapeutic agents causing severe nausea and vomiting. Most oncologists based their choice of antiemetics on personal experience. Current literature addressing the treatment of nausea and vomiting in children receiving chemotherapy, as reviewed here, does not always support the present clinical practices.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2058609

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  3 in total

1.  Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children.

Authors:  I Tejedor; A Idoate; M Jiménez; L Sierrasesumaga; J Giráldez
Journal:  Pharm World Sci       Date:  1999-04

2.  The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets.

Authors:  H E Marr; P T Davey; E A Boyle; P R Blower
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Audit of guidelines for effective control of chemotherapy and radiotherapy induced emesis.

Authors:  A B Foot; C Hayes
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.